Eickhoff, Matthias

[["dc.bibliographiccitation.firstpage","478"],["dc.bibliographiccitation.issue","2-3"],["dc.bibliographiccitation.journal","Schizophrenia Research"],["dc.bibliographiccitation.lastpage","486"],["dc.bibliographiccitation.volume","152"],["dc.contributor.author","Gaebel, Wolfgang"],["dc.contributor.author","Riesbeck, Mathias"],["dc.contributor.author","Woelwer, Wolfgang"],["dc.contributor.author","Klimke, Ansgar"],["dc.contributor.author","Eickhoff, Matthias"],["dc.contributor.author","von Wilmsdorff, Martina"],["dc.contributor.author","Heuser, Isabella"],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Klosterkoetter, Joachim"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Schloesser, Ralf G. M."],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Riedel, Michael"],["dc.contributor.author","Klingberg, Stefan"],["dc.contributor.author","Koepcke, Wolfgang"],["dc.contributor.author","Ohmann, Christian"],["dc.contributor.author","Moeller, Hans-Juergen"],["dc.date.accessioned","2018-11-07T09:44:42Z"],["dc.date.available","2018-11-07T09:44:42Z"],["dc.date.issued","2014"],["dc.description.abstract","Objective: Full and sustained symptom remission is a major treatment objective after a first-episode in schizophrenia. Findings regarding differences in remission between first-and second-generation antipsychotics are inconclusive. This study aimed to provide rates and predictors of remission in first-episode schizophrenia and to identify symptoms that prevent remission. Methods: Prevalence rates of \"symptomatic remission\" (symptom criteria only) and \"enduring remission\" (symptom and 6-month time criteria), defined according to Andreasen et al. (2005), were determined in first-episode patients participating in a RCT by the German Research Network on Schizophrenia (GRNS) that compared post-acute, 1-year maintenance treatment with risperidone or haloperidol. Respective predictors at baseline were identified by logistic and Cox regression analysis. Results: Prevalence rates were 91.5% for symptomatic remission (n = 152/166 eligible patients) and 58.6% for enduring remission (n = 65 of 111 patients who continued for at least 6 months; 39.2% of all 166 patients included), with no significant differences between risperidone and haloperidol in either type of remission. Enduring remission often was not reached because of negative symptoms: After 6 months, 40.5% of the patients had at least 1 negative symptom, whereas only 10.8% of the patients had \"persisting\" positive symptoms. Of the different predictors identified in univariate analyses, (lower) negative symptoms and participating in standardized psychological treatment remained significant in multivariate (stepwise forward) analyses for enduring remission. Conclusions: By far most of the first-episode patients reached a temporary state of full symptomatic remission within 1 year of antipsychotic treatment. However, only about 50% achieved sustained, enduring remission. Negative symptoms are still a major treatment obstacle to enduring remission in schizophrenia. (C) 2013 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.schres.2013.04.012"],["dc.identifier.isi","000330188500022"],["dc.identifier.pmid","23643327"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34451"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1573-2509"],["dc.relation.issn","0920-9964"],["dc.title","Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","205"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","The Journal of Clinical Psychiatry"],["dc.bibliographiccitation.lastpage","218"],["dc.bibliographiccitation.volume","72"],["dc.contributor.author","Gaebel, Wolfgang"],["dc.contributor.author","Riesbeck, Mathias"],["dc.contributor.author","Woelwer, Wolfgang"],["dc.contributor.author","Klimke, Ansgar"],["dc.contributor.author","Eickhoff, Matthias"],["dc.contributor.author","von Wilmsdorff, Martina"],["dc.contributor.author","Lemke, Matthias R."],["dc.contributor.author","Heuser, Isabella"],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Huff, Wolfgang"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Sauer, Heinrich"],["dc.contributor.author","Riedel, Michael"],["dc.contributor.author","Klingberg, Stefan"],["dc.contributor.author","Koepcke, Wolfgang"],["dc.contributor.author","Ohmann, Christian"],["dc.contributor.author","Moeller, Hans-Juergen"],["dc.date.accessioned","2018-11-07T08:59:50Z"],["dc.date.available","2018-11-07T08:59:50Z"],["dc.date.issued","2011"],["dc.description.abstract","Objective: After acute treatment of the first illness episode in schizophrenia, antipsychotic maintenance treatment is recommended for at least 1 year. Evidence for the optimal subsequent treatment is still scarce. Targeted intermittent treatment was found to be less effective than continuous treatment at preventing relapse in multiple episode patients; however, a post hoc analysis of our own data from a previous study suggested comparable efficacy of the 2 treatment approaches in first-episode patients. The current study was therefore designed to compare prospectively the relapse preventive efficacy of further maintenance treatment and targeted intermittent treatment in patients with ICD-10 diagnosed first-episode schizophrenia. Method: A randomized controlled trial was conducted within the German Research Network on Schizophrenia. Entry screening took place between November 2000 and May 2004. After 1 year of antipsychotic maintenance treatment, stable first-episode patients were randomly assigned to 12 months of further maintenance treatment or stepwise drug discontinuation and targeted intermittent treatment. In case of prodromal symptoms of an impending relapse, patients in both groups received early drug intervention, guided by a decision algorithm. The primary outcome measure was relapse (increase in the Positive and Negative Syndrome Scale positive score > 10, Clinical Global Impressions-Change score 6, and decrease in Global Assessment of Functioning score > 20 between 2 visits). Results: Of 96 first-episode patients, only 44 were eligible for the assigned treatment (maintenance treatment, n = 23; intermittent treatment, n = 21). The rates of relapse (19% vs 0%; P=.04) and deterioration (up to 57% vs 4%; P < .001) were significantly higher in the intermittent treatment group than in the maintenance treatment group, but quality-of-life scores were comparable. Intermittent treatment patients received a significantly lower amount of antipsychotics (in haloperidol equivalents; P < .001) and tended to show fewer side effects, particularly extrapyramidal side effects. Conclusions: Maintenance treatment is more effective than targeted intermittent treatment in preventing relapse, even in stable first-episode patients after 1 year of maintenance treatment, and should be the preferred treatment option. However, about 50% of patients remain stable at a significantly lower drug dose and show fewer side effects, and a substantial proportion refuse maintenance treatment. Alternative long-term treatment strategies, including targeted intermittent treatment, should therefore be provided in individual cases. Trial Registration: clinicaltrials.gov Identifier: NCT00159120 J Clin Psychiatry 2011;72(2):205-218 (C) Copyright 2010 Physicians Postgraduate Press, Inc."],["dc.identifier.doi","10.4088/JCP.09m05459yel"],["dc.identifier.isi","000287985400010"],["dc.identifier.pmid","20673559"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24001"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Physicians Postgraduate Press"],["dc.relation.issn","0160-6689"],["dc.title","Relapse Prevention in First-Episode Schizophrenia-Maintenance vs Intermittent Drug Treatment With Prodrome-Based Early Intervention: Results of a Randomized Controlled Trial Within the German Research Network on Schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","168"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Schizophrenia Research"],["dc.bibliographiccitation.lastpage","176"],["dc.bibliographiccitation.volume","170"],["dc.contributor.author","Gaebel, Wolfgang"],["dc.contributor.author","Riesbeck, Mathias"],["dc.contributor.author","Woelwer, Wolfgang"],["dc.contributor.author","Klimke, Ansgar"],["dc.contributor.author","Eickhoff, Matthias"],["dc.contributor.author","von Wilmsdorff, Martina"],["dc.contributor.author","de Millas, Walter"],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Ruhrmann, Stephan"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Sauer, Heinrich"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Riedel, Michael"],["dc.contributor.author","Klingberg, Stefan"],["dc.contributor.author","Moeller, Hans-Juergen"],["dc.date.accessioned","2018-11-07T10:21:37Z"],["dc.date.available","2018-11-07T10:21:37Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: After a first episode in schizophrenia guidelines recommend antipsychotic maintenance treatment (MT) for at least 1 year. Recent RCTs on subsequent targeted intermittent treatment (IT) after stepwise drug discontinuation yielded noticeably higher relapse rates than during MT also in first-episode patients. Nevertheless, about 50% of patients remain stable under IT. Given the potential adverse effects of antipsychotics and the preference of many patients to discontinue drugs, valid predictors for the feasibility of IT are urgently needed to support decision making. Methods: Based on a one-year RCT phase comparing MT with IT in first-episode patients after 1 year of MT, conducted within the German Research Network on Schizophrenia (GRNS), predictors for deterioration under IT in 19 feasible patients were identified by logistic regression analysis. Results: Deterioration occurred in 10 patients (52.6%). Univariate analyses indicated a lower PANSS positive score after acute treatment as well as after one year of MT as significant predictors; in multivariate logistic regression, in addition to the lower PANSS positive score after acute treatment, reaching enduring remission and having had a deterioration both during MT evolved as significant predictors and indicate a higher risk for deterioration. Conclusions: Although limited by the small sample size, our findings suggest that patients who show a favorable response and full and enduring symptom remission during antipsychotic treatment, as well as those with marked deterioration despite MT should rather be recommended to remain on treatment because they are at higher risk for symptom re-exacerbation after (stepwise) drug discontinuation. (C) 2015 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.schres.2015.10.024"],["dc.identifier.isi","000367535500022"],["dc.identifier.pmid","26607102"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42126"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1573-2509"],["dc.relation.issn","0920-9964"],["dc.title","Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia Results of the first-episode study within the German research network on schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1763"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","The Journal of Clinical Psychiatry"],["dc.bibliographiccitation.lastpage","1774"],["dc.bibliographiccitation.volume","68"],["dc.contributor.author","Gaebel, Wolfgang"],["dc.contributor.author","Riesbeck, Mathias"],["dc.contributor.author","Woelwer, Wolfgang"],["dc.contributor.author","Klimke, Ansgar"],["dc.contributor.author","Eickhoff, Matthias"],["dc.contributor.author","von Wilmsdorff, Martina"],["dc.contributor.author","Jockers-Scheruebl, Maria C."],["dc.contributor.author","Kuehn, Kai-Uwe"],["dc.contributor.author","Lemke, Matthias R."],["dc.contributor.author","Bechdolf, Andreas"],["dc.contributor.author","Bender, Stefan"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Schloesser, Ralf G. M."],["dc.contributor.author","Schmidt, Lutz G."],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Jaeger, Markus"],["dc.contributor.author","Buchkremer, Gerd"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Klingberg, Stefan"],["dc.contributor.author","Koepcke, Wolfgang"],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Haefner, Heinz"],["dc.contributor.author","Ohmann, Christian"],["dc.contributor.author","Salize, Hans J."],["dc.contributor.author","Schneider, Frank"],["dc.contributor.author","Moeller, Hans-Juergen"],["dc.date.accessioned","2018-11-07T10:57:11Z"],["dc.date.available","2018-11-07T10:57:11Z"],["dc.date.issued","2007"],["dc.description.abstract","Objective: Second-generation antipsychotics (SGAs) have proven superior to first-generation antipsychotics regarding relapse prevention, mainly in multiple-episode patients. Practice guidelines recommend SGAs as first-line treatment particularly in first-episode patients, although evidence for this group is still limited. Accordingly, the hypothesis of whether 1-year relapse rate in first-episode schizophrenia under maintenance treatment with risperidone is lower compared to haloperidol in low dose was tested. Method: Between November 2000 and May 2004, 1372 patients had been screened for eligibility in the inpatient facilities of 13 German psychiatric university hospitals. 159 remitted patients were enrolled after treatment of an acute first episode of schizophrenia according to ICD-10 F20 criteria. In the randomized controlled trial, double-blind antipsychotic treatment with risperidone or haloperidol was maintained in a targeted dose of 2 to 4 mg/day for 1 year. 151 patients were eligible for analysis. For 127 patients, this was a continuation trial after 8 weeks of randomized, double-blind, acute treatment with the same drugs; 24 patients were additionally randomly assigned after open acute treatment. Results: With both antipsychotics (risperidone, N = 77; haloperidol, N = 74), no relapse evolved. Additionally, according to 2 post hoc defined measures of \"marked clinical deterioration,\" significant differences occurred neither in the 2 respective deterioration rates (risperidone = 9%/23%; haloperidol = 8%/22%) nor in time until deterioration. Both antipsychotics were equally effective regarding significant symptom reduction and improvement in quality of life. Extrapyramidal symptoms were slightly higher with haloperidol. The overall dropout rate of 68%, however, was not significantly different between the 2 drug groups. Conclusion: Against the background of an overall favorable outcome, the hypothesized difference between risperidone and low-dose haloperidol regarding relapse prevention could not be supported for this sample of patients with firstepisode schizophrenia. Possible design-related reasons for this finding are discussed. With regard to the high dropout rate, special programs are needed to keep schizophrenia patients who are in their early acute and postacute illness course in effective and safe treatment."],["dc.identifier.isi","000251179200016"],["dc.identifier.pmid","18052570"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50183"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Physicians Postgraduate Press"],["dc.relation.issn","0160-6689"],["dc.title","Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-Year results of a randomized controlled trial within the German research network on schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]